Segment, Geographical and Other Revenue Information (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Schedule of segment reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

	Three months ended September 30, 2018							Three months ended September 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total			Performance Enzymes			Novel Biotherapeutics			Total
Revenues:
Product revenue	$	8,405	$	—	$	8,405		$	6,948		$	—		$	6,948
Research and development revenue	3,720		4,821		8,541			3,036			—			3,036
Total revenues	12,125		4,821		16,946			9,984			—			9,984
Costs and operating expenses:
Cost of product revenue	3,791		—		3,791			3,976			—			3,976
Research and development(1)	4,758		2,920		7,678			4,410			3,474			7,884
Selling, general and administrative	1,870		165		2,035			1,649			—			1,649
Total segment costs and operating expenses	10,419		3,085		13,504			10,035			3,474			13,509
Income (loss) from operations	$	1,706	$	1,736	$	3,442		$	(51	)	$	(3,474	)	$	(3,525	)
Corporate costs (2)					(5,120		)							(6,310		)
Depreciation					(309		)							(241		)
Loss before income taxes					$	(1,987	)							$	(10,076	)

⁽¹⁾ Research and development expenses exclude depreciation.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

	Nine months ended September 30, 2018							Nine months ended September 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total			Performance Enzymes			Novel Biotherapeutics			Total
Revenues:
Product revenue	$	18,291	$	—	$	18,291		$	19,134		$	—		$	19,134
Research and development revenue	15,728		10,507		26,235			9,167			—			9,167
Total revenues	34,019		10,507		44,526			28,301			—			28,301
Costs and operating expenses:
Cost of product revenue	10,228		—		10,228			10,768			—			10,768
Research and development(1)	14,548		7,294		21,842			12,582			7,134			19,716
Selling, general and administrative	5,695		615		6,310			5,238			—			5,238
Total segment costs and operating expenses	30,471		7,909		38,380			28,588			7,134			35,722
Income (loss) from operations	$	3,548	$	2,598	$	6,146		$	(287	)	$	(7,134	)	$	(7,421	)
Corporate costs (2)					(15,762		)							(15,618		)
Depreciation					(812		)							(795		)
Loss before income taxes					$	(10,428	)							$	(23,834	)

⁽¹⁾ Research and development expenses exclude depreciation.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):

	Three months ended September 30, 2018						Three months ended September 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	354	$	97	$	451	$	607	$	55	$	662

	Nine months ended September 30, 2018						Nine months ended September 30, 2017
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Stock-based compensation	$	2,005	$	243	$	2,248	$	1,670	$	154	$	1,824

Schedule of customers that contributed 10% or more of total accounts receivable

Customers that each contributed 10% or more of our total revenues were as follows:

	Percentage of Total Revenues for the
	Three Months Ended September 30,		Nine Months Ended September 30,
	2018	2017	2018	2017
Customer A	27%	27%	33%	37%
Customer B	28%	*	24%	*
Customer C	10%	11%	17%	11%
Customer D	15%	29%	11%	18%
Customer E	*	10%	*	*

Customers that each contributed 10% or more of our total accounts receivable had the following balances as of the periods presented:

	Percentage of Accounts Receivables at
	September 30, 2018	December 31, 2017
Customer A	45%	31%
Customer B	10%	*
Customer C	*	16%
Customer D	10%	15%
Customer F	*	14%
Customer G	11%	*

* Less than 10% of the period presented

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Revenues
Americas	$	4,315	$	3,606	$	13,968	$	9,795
EMEA	6,274		3,415		15,075		8,581
APAC	6,357		2,963		15,483		9,925
Total revenues	$	16,946	$	9,984	$	44,526	$	28,301

Schedule of long-lived assets by geographical area

Identifiable long-lived assets as follows (in percentage):

Long-lived assets:	September 30, 2018		December 31, 2017
United States	100	%	100	%